The Translational Research Institute (TRI) began operations in 2012 under the leadership of Emeritus Professor Ian Frazer AC, co-founder of the Gardasil cervical cancer vaccine, as its inaugural CEO. Located within Brisbane’s biomedical knowledge corridor - just 15 minutes from the International Airport - TRI is the only institute of its kind in Australia and a global leader in translating research into real-world healthcare solutions.
In partnership with The University of Queensland, QUT, Mater Research and Queensland Health, TRI offers world-class facilities that integrate research, preclinical and clinical trials, and manufacturing capabilities, creating a unique environment where discovery, innovation, and translation flourish. It is home to over 1,100 researchers, clinicians, and industry professionals working to advance biomedical discoveries from bench to bedside and drive them through preclinical and clinical trials to commercial success.
By 2026, TRI will become Australia’s largest translational research campus and the first in the country to offer open-access, cGMP (current Good Manufacturing Practice) manufacturing facilities. This state-of-the-art facility will offer on-demand cGMP manufacturing for maturing and innovative biotech, pharma and medtech companies in the development of RNA-based therapies, cell and gene therapies, biologics, vaccines, and drug-device combination products.
The new facility is designed to meet both international and Australian regulatory standards, including all relevant cGMP and ISO requirements. Tenants will have access to Grade B cGMP cleanrooms, PC2-compliant wet labs, and dedicated office space, enabling them to conduct their own manufacturing, onsite quality control, and process and analytical development.
In addition, tenants will benefit from on-site technical support, training, and access to cGMP expertise. These resources will help companies establish robust manufacturing processes, scale up production, and conduct ongoing cGMP manufacturing for Phase 1 to Phase 3 clinical trials in compliance with global standards.
Why work with us
At the Translational Research Institute (TRI) and our new Translational Manufacturing facility, we provide a unique end-to-end ecosystem that bridges the gap between discovery and real-world impact. As Australia’s only integrated translational research and advanced manufacturing hub, we offer unparalleled access to world-class infrastructure, scientific expertise, and regulatory-grade cleanroom facilities - all under one roof.
Whether you're an emerging biotech, an established pharma company, or an academic researcher, working with us means gaining a strategic partner committed to accelerating your journey from bench to bedside. Our on-demand cGMP manufacturing capabilities, regulatory-aligned quality systems, and supportive tenancy model ensure that your innovations are developed, tested, and scaled to global standards.
Collaborate with TRI to unlock faster clinical translation, reduce development risks, and bring life-changing therapies to patients - sooner.
